title: Transplantation for Multiple Myeloma.
abstract: Multiple myeloma is a disorder characterized by accumulation of malignant plasma cells in the bone marrow, hypercalcemia, monoclonal protein, and end organ damage. Recently newer generation proteosome inhibitors, monoclonal antibodies and novel agents have been approved by FDA, which is undoubtedly increasing life expectancy of the patients. However, hematopoietic stem cell transplantation still remains the cornerstone of the treatment. In this chapter, we are discussing the autologous stem cell transplant, allogeneic stem cell transplant and total therapy trials with outcomes.
authors.affiliation: Stem Cell and Allogeneic Transplant, Department of Hematology/Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA. YSJethava@uams.edu.
authors.forename: Yogesh S
authors.initials: YS
authors.lastname: Jethava
authors.affiliation: Stem Cell and Allogeneic Transplant, Department of Hematology/Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: Frits
authors.initials: F
authors.lastname: van Rhee
mesh_terms: D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009101:Multiple Myeloma / Q000628:therapy*
keywords: Clinical trials with transplant; Myeloma; Stem cell transplant; Tandem transplants